Compare GRPN & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRPN | REPL |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 723.4M | 781.3M |
| IPO Year | 2011 | 2018 |
| Metric | GRPN | REPL |
|---|---|---|
| Price | $16.27 | $8.94 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $31.25 | $12.00 |
| AVG Volume (30 Days) | 980.2K | ★ 1.3M |
| Earning Date | 11-06-2025 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $496,093,000.00 | N/A |
| Revenue This Year | $4.17 | N/A |
| Revenue Next Year | $10.63 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.21 | $2.68 |
| 52 Week High | $43.08 | $14.80 |
| Indicator | GRPN | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 40.49 | 43.30 |
| Support Level | $17.43 | $8.23 |
| Resistance Level | $17.93 | $9.99 |
| Average True Range (ATR) | 0.71 | 0.45 |
| MACD | -0.01 | -0.20 |
| Stochastic Oscillator | 15.72 | 36.43 |
Groupon Inc acts as the middleman between consumers and merchants, offering products and services at discounts via its online store. It offers consumers daily deals from local merchants. The company's operations are organized into two segments: North America and International. The company generates the majority of its revenue from North America. The company generates revenue from transactions during which the company generates commissions by selling goods or services on behalf of third-party merchants. Revenue also includes commissions the company earn when customers make purchases with retailers using digital coupons accessed through its digital properties.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.